ArticleFrontiers in oncology2025
Development and validation of a clinical model to predict low-grade intraepithelial neoplasia in chronic atrophic gastritis patients: a retrospective observational multicenter analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic atrophic gastritis (CAG), an early stage of gastric cancer, is a major digestive disorder, and the prognosis of CAG is determined by many sociodemographic and clinicopathologic subject characteristics. This retrospective observational multicenter analysis was conducted to explore risk factors and construct a predictive model for low-grade intraepithelial neoplasia (LGIN) in patients with CAG. Methods: The training dataset included 317 CAG patients diagnosed and treated in the Second Affiliated Hospital of Anhui University of Chinese Medicine from September 2018 to January 2025. All the baseline characteristics, including gender, age, education, basic diseases, blood indicators, and pathological mechanism during treatment of CAG, were recorded and selected based on both the least absolute shrinkage and selection operator (LASSO) regression analysis with 10-fold cross-validation and logistic regression analysis. After that, the nomogram was established, and its accuracy and predictive performance were evaluated via the area under the receiver operating characteristic (ROC) curves (AUC), calibration curves, Hosmer-Lemeshow goodness-of-fit test, and decision curve analysis (DCA) curves. For the validation dataset, the medical record information of 92 CAG patients diagnosed and treated in the Hefei Second People's Hospital from November 2023 to January 2025 was recorded for subsequent analysis. Results: Our LASSO regression analysis revealed that family history, HP infection, pepsinogen I, pepsinogen II, bile reflux, and Kimura-Takemoto classification (C3 vs. C1) were significant independent risk factors, and the fitting equation was obtained. A nomogram for predicting LGIN in CAG patients was established. The ROC curve revealed that our predictive model showed good predictive efficacy with an AUC value of 0.838 (95% CI = 0.789-0.887) with a specificity of 0.761 and a sensitivity of 0.791 in the training dataset and an AUC value of 0.941 (95% CI = 0.893-0.989) with a specificity of 0.852 and a sensitivity of 0.908 in the validation dataset. Moreover, calibration and DCA curves demonstrated that our predictive model had a good fit, better net benefit, and predictive efficiency in LGIN in CAG patients. Conclusions: Our predictive model demonstrated that family history, HP infection, pepsinogen I, pepsinogen II, bile reflux, and Kimura-Takemoto classification were the independent risk factors of LGIN in CAG patients with high accuracy and good calibration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.